![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, November 15, 2023 9:50:09 AM
Recent CMMB News
- Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis • GlobeNewswire Inc. • 06/18/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/12/2024 08:02:17 PM
- Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference • GlobeNewswire Inc. • 06/06/2024 11:00:00 AM
- Chemomab Therapeutics to Participate in Upcoming Scientific Conferences • GlobeNewswire Inc. • 05/17/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/09/2024 11:00:40 AM
- Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/09/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2024 11:05:07 AM
- Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update • GlobeNewswire Inc. • 04/24/2024 11:00:00 AM
- Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis • GlobeNewswire Inc. • 04/18/2024 11:00:00 AM
- Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024 • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis • GlobeNewswire Inc. • 03/25/2024 11:06:46 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/07/2024 12:00:10 PM
- Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update • PR Newswire (US) • 03/07/2024 12:00:00 PM
- Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference • PR Newswire (US) • 03/05/2024 12:00:00 PM
- Biotech Shares Massively Bid Up Before Opening Bell • AllPennyStocks.com • 02/20/2024 02:20:00 PM
- Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases • PR Newswire (US) • 02/20/2024 12:00:00 PM
- Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update • PR Newswire (US) • 02/14/2024 12:00:00 PM
- Chemomab Therapeutics to Participate in Upcoming Investor Conferences • PR Newswire (US) • 02/05/2024 12:00:00 PM
- Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis • PR Newswire (US) • 01/30/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/03/2024 12:00:16 PM
- Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024 • PR Newswire (US) • 01/03/2024 12:00:00 PM
- Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis • PR Newswire (US) • 11/16/2023 12:00:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 11/15/2023 09:35:45 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM